IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
Sarah Harris 1
Rachel Maddux 1
Yicong Li 2
Sarah Hu 2
Chun Wu 2
AnnKatrin Petersen 2
1 Bristol Myers Squibb, Princeton, United States
2 Parexel International, Durham, United States
Session
IBD (Posters)
Conference
UEG Week Vienna 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]